Supernus Pharmaceuticals Earnings: Here’s Why Investors are Ambivalent Now
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Supernus Pharmaceuticals Inc Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.89 in the quarter versus EPS of $-0.61 in the year-earlier quarter.
Revenue: Rose 211.11% to $280,000 from the year-earlier quarter.
Actual vs. Wall St. Expectations: Supernus Pharmaceuticals Inc reported adjusted EPS loss of $0.89 per share. By that measure, the company missed the mean analyst estimate of $-0.65. It beat the average revenue estimate of $0.
Quoting Management: “Oxtellar XRTM continues to impress us with its clinical performance in the market. Prescribers are highly satisfied with the product and patients appreciate its key benefits. We are pleased with continued growth in the prescriber base and monthly prescriptions as we head into the middle of the third quarter. We also remain excited about our preparations for the upcoming launch of Trokendi XRTM later this quarter,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals, Inc.
Key Stats (on next page)…